Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02353299
Recruitment Status : Completed
First Posted : February 2, 2015
Results First Posted : December 7, 2017
Last Update Posted : January 2, 2018
Sponsor:
Collaborator:
Henry Ford Hospital
Information provided by (Responsible Party):
Pernix Theraputics LLC

Brief Summary:
This is a Phase IV, randomized, double-blind, placebo-controlled, four-arm crossover study. The study will assess the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective T-max in normal healthy adult male volunteers. The study will be conducted in approximately 52 male subjects

Condition or disease Intervention/treatment Phase
Healthy Drug: Silenor 6 mg Drug: zolpidem 10 mg Drug: Placebo Phase 4

Detailed Description:

Subjects will be screened and asked to complete sleep disorders questionnaires and a sleep diary to establish normal sleep patterns and to rule out any sleep disorder.

Eligible subjects will be scheduled for a Screening PSG to rule out PLMS, sleep apnea and other sleep disorders.

Subjects who meet the screening PSG criteria will be randomly assigned to a treatment sequence order that involves both the study drug and the time subjects are awakened in the middle-of-the-night using a crossover study design. These four sequences include Silenor 6 mg with a middle-of-the-night awakening at 4 hours (DXP-4H), zolpidem 10 mg with a middle-of-the-night awakening at 1.5 hours (ZOL-1.5H), placebo with a middle-of-the-night awakening at 4 hours (PBO-4H), and placebo with a middle-of-the-night awakening at 1.5 hours (PBO-1.5H). Study drug will be administered under fasted conditions (at least 4 hours) as a single dose at bedtime (approximately 2300 hours), and each subject will receive one dose of each active drug (Silenor 6 mg and zolpidem 10 mg), and two doses of placebo during the treatment period.

Safety assessments will be performed throughout the study.

During the night of assessment, subjects will be awoken at the estimated T-max of the active drugs, with a matching placebo group awakened at each of these time points with the same arousability protocol. Arousability will be assessed using the Auditory Awakening Threshold test (AAT) .

Once the Auditory Awakening Threshold has been determined, subjects will perform a Tandem Walk assessment followed by the Berg Balance Scale (BBS) and finally by Free Recall Memory testing.

Subjects will be discharged from the sleep center once all assessments have been completed. A final study visit will be performed for subjects either after they have completed all four Treatment Periods or they have prematurely discontinued the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: Phase IV 4 Way Crossover Study to Assess and Compare the Effect of a Single Nighttime Administration of Zolpidem, Silenor and Placebo on Arousability, Ataxia/Balance and Cognitive Performance in Healthy Volunteers.
Study Start Date : January 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : March 2016


Arm Intervention/treatment
Active Comparator: Silenor 6 mg (DXP-4H)
Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
Drug: Silenor 6 mg
Silenor 6 mg single nighttime dose.
Other Name: doxepin

Drug: zolpidem 10 mg
Zolpidem 10 mg single nighttime dose
Other Name: zolpidem

Drug: Placebo
placebo single nighttime dose-1.5 hours

Drug: Placebo
placebo single nighttime dose-4 hours

Placebo Comparator: Placebo (PBO-4H)
placebo single nightime dose -4 hour post dose arousability and cognitive assessments
Drug: Silenor 6 mg
Silenor 6 mg single nighttime dose.
Other Name: doxepin

Drug: zolpidem 10 mg
Zolpidem 10 mg single nighttime dose
Other Name: zolpidem

Drug: Placebo
placebo single nighttime dose-1.5 hours

Drug: Placebo
placebo single nighttime dose-4 hours

Active Comparator: Zolpidem 10 mg (ZOL-1.5H)
zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
Drug: Silenor 6 mg
Silenor 6 mg single nighttime dose.
Other Name: doxepin

Drug: zolpidem 10 mg
Zolpidem 10 mg single nighttime dose
Other Name: zolpidem

Drug: Placebo
placebo single nighttime dose-1.5 hours

Drug: Placebo
placebo single nighttime dose-4 hours

Placebo Comparator: Placebo (PBO-1.5H)
placebo single nightime dose -1.5 hour arousability and cognitive assessments
Drug: Silenor 6 mg
Silenor 6 mg single nighttime dose.
Other Name: doxepin

Drug: zolpidem 10 mg
Zolpidem 10 mg single nighttime dose
Other Name: zolpidem

Drug: Placebo
placebo single nighttime dose-1.5 hours

Drug: Placebo
placebo single nighttime dose-4 hours




Primary Outcome Measures :
  1. Auditory Arousal Threshold (AAT) at T-max [ Time Frame: at either 1.5 or 4 hours post dose ]

    AAT will performed at T-max for Silenor and matching placebo at 4 hours post dose. Assessments performed at t max for zolpidem and placebo at 1.5 hours post dose.

    An acoustic stimulus (1000 Hz tone) was presented through audiometric earphones (E-A-RTone 3A Insert Earphones). Tones began at 30 dB and increased by 5 dB until the participant woke up or the maximum dB-level (110 dB) was reached.



Secondary Outcome Measures :
  1. Tandem Walk Step-Offs [ Time Frame: at either 1.5 or 4 hours post dose ]

    Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.

    Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoints were the number of step-offs from the beam.


  2. Tandem Walk Duration Over Five Trials [ Time Frame: at either 1.5 or 4 hours post dose ]

    Tandem walk will be performed at T-max for Silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.

    Fall risk as impacted by balance was measured using the Tandem Walk Test (TWT), which assesses balance via a method of walking in which the toes of the back foot must touch the heel of the front foot at each step; this elicits postural control by reducing the base of support compared to normal walking. Endpoint: mean completion duration over five trials.


  3. Berg Balance Test [ Time Frame: at either 1.5 or 4 hours post dose ]

    Berg Balance will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.

    Fall risk as impacted by gait was measured using the Berg Balance Scale (BBS). The BBS is a widely used clinical test of static and dynamic balance abilities. Comprising of 14 simple balance-related tasks, ranging from standing up from a sitting position to standing on one foot, the BBS takes 15-20 minutes to complete. Each component task is scored on a Likert scale: 0 (unable to perform) to 4 (performed independently). The sum of component scores yields the final BBS score (0-20: high fall risk; 21-40: medium fall risk; 41-56: low fall risk).


  4. Immediate Free Recall Task [ Time Frame: directly after the encoding task ]

    Immediate Free Recall will be performed at T-max for silenor and matching placebo at 4 hours post dose and at 1.5 hours post dose for zolpidem 10 mg and matching placebo.

    Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session.


  5. Delayed Free Recall Task [ Time Frame: 15 minutes after final awakening the morning ]

    Delayed Free Recall Task was performed 15 minutes after final awakening the morning

    Free Recall is a basic paradigm in the psychological study of memory. In this paradigm, participants were presented with a total of 16 words serially. They were informed prior to the task that memory for the presented words would be tested later in the session. Participants were asked to recall as many words as they can 15 minutes after final awakening in the morning


  6. Number of Participants With Adverse Events [ Time Frame: throughout the study until the final study visit, up to 6 weeks ]
    Adverse events were defined by any negative event experienced by a participant during the study (assessed in the morning prior to participants leaving the lab) and included the washout period following each treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be in good general health as determined by the investigator;
  • Have a 3-month history of a normal nightly sleep pattern based on the subject's self report ;
  • A usual time in bed
  • A regular bedtime between 2200 and 2400 hours
  • No habitual daytime napping;
  • Epworth Sleepiness Scale score ≤ 10;
  • Be able to read, understand, and provide written/dated informed consent before enrolling in the study, and must be willing and able to comply with all study procedures;
  • Be able to follow verbal and written instructions provided in English

Exclusion Criteria:

  • Have a body mass index (BMI) >35 kg/m2
  • Have symptoms consistent with the diagnosis of any sleep disorder (e.g., insomnia, sleep apnea, narcolepsy, periodic leg movements, or restless leg syndrome);
  • On screening PSG AHI > 10 or PLMAI >10;
  • Have a known or suspected diagnosis of Acquired Immune Deficiency Syndrome (AIDS), or have tested seropositive for human immunodeficiency virus (HIV) antibody or antigen previously;
  • Have any clinically significant abnormal finding in physical examination, neurological assessment, vital signs, elevated body temperature, or clinical laboratory tests, as determined by the Investigator;
  • Have a known exaggerated pharmacological sensitivity, hypersensitivity, or history of a clinically significant adverse reaction to zolpidem;
  • Have a known or exaggerated pharmacological sensitivity, hypersensitivity, or intolerance to doxepin HCl, any tricyclic antidepressant, or antihistamine;
  • Currently taking cimetidine or a monoamine oxidase inhibitor (MAOI);
  • Current diagnosis of severe urinary retention;
  • Current diagnosis of untreated glaucoma;
  • Intends to use any medication including over-the-counter (OTC) medications that would interfere with normal sleep architecture (such as systemic steroids, beta-adrenergic blockers, amphetamines, modafinil, etc.);
  • Self-reports use of products containing nicotine of greater than 15 cigarettes daily, or cannot avoid products containing nicotine during the normal sleep periods;
  • Self report consumption of more than five alcoholic beverages on any one day or greater than 14 alcoholic beverages weekly over the past week;
  • Have a history of epilepsy or serious head injury;
  • Used CYP450 2D6 inducers or inhibitors within 7 days before screening;
  • Have used prescribed or OTC medications within 30 days of screening (Day 0) or intend to use any prescription or OTC medication during the study that may interfere with the evaluation of the study drug.
  • Have used an investigational drug within 30 days or five half lives (whichever is longer) before screening, or plans to use an investigational drug during the study or have used doxepin or zolpidem previously.
  • Score of < 40 on the BBS at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353299


Locations
Layout table for location information
United States, Michigan
Henry Ford Hospital Sleep Disorders & Research Center
Novi, Michigan, United States, 48377
Sponsors and Collaborators
Pernix Theraputics LLC
Henry Ford Hospital
Investigators
Layout table for investigator information
Principal Investigator: Chris Drake, PhD Henry Ford Hospital Sleep Disorder Research Center

Publications of Results:
Other Publications:
Davis KL, Charey D, Cuyle JT, Nemeroff C. Neuropsychopharmacology, The Fifth Generation of Progress. 2002; Section 13: 1938-1939
Silenor [prescribing information]. Pernix Pharmaceuticals, Inc., San Diego, CA; March 2010.
Sanofi-Synthelabo. Ambien (zolpidem tartrate) complete prescribing information. 2002.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pernix Theraputics LLC
ClinicalTrials.gov Identifier: NCT02353299     History of Changes
Other Study ID Numbers: PT-D1402
First Posted: February 2, 2015    Key Record Dates
Results First Posted: December 7, 2017
Last Update Posted: January 2, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pernix Theraputics LLC:
Cognition
Balance
Additional relevant MeSH terms:
Layout table for MeSH terms
Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Zolpidem
Doxepin
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Histamine Antagonists
Histamine Agents